Abstract
For ethical reasons, testing the efficacy of new treatments for chronic diseases such as osteoporosis has hit a brick wall. Furthermore, existing trial designs, although satisfying requirements for drug registration, typically produce results with limited generalizability. Compounding the problem, these results often serve as the basis for treatment guidelines, which, in turn, are assembled by policy-makers and analysts who often do not understand the biology of the systems concerned. In this perspective, the details of these problems are briefly described and the broad outlines of some solutions suggested.
| Original language | English |
|---|---|
| Pages (from-to) | 105-110 |
| Number of pages | 6 |
| Journal | Future Rheumatology |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2007 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Rheumatology
Cite this
Evidence-based medicine and common sense : Practical and ethical issues in clinical trials for osteoporosis. / Heaney, Robert P.
In: Future Rheumatology, Vol. 2, No. 1, 02.2007, p. 105-110.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evidence-based medicine and common sense
T2 - Practical and ethical issues in clinical trials for osteoporosis
AU - Heaney, Robert P.
PY - 2007/2
Y1 - 2007/2
N2 - For ethical reasons, testing the efficacy of new treatments for chronic diseases such as osteoporosis has hit a brick wall. Furthermore, existing trial designs, although satisfying requirements for drug registration, typically produce results with limited generalizability. Compounding the problem, these results often serve as the basis for treatment guidelines, which, in turn, are assembled by policy-makers and analysts who often do not understand the biology of the systems concerned. In this perspective, the details of these problems are briefly described and the broad outlines of some solutions suggested.
AB - For ethical reasons, testing the efficacy of new treatments for chronic diseases such as osteoporosis has hit a brick wall. Furthermore, existing trial designs, although satisfying requirements for drug registration, typically produce results with limited generalizability. Compounding the problem, these results often serve as the basis for treatment guidelines, which, in turn, are assembled by policy-makers and analysts who often do not understand the biology of the systems concerned. In this perspective, the details of these problems are briefly described and the broad outlines of some solutions suggested.
UR - http://www.scopus.com/inward/record.url?scp=34249284853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249284853&partnerID=8YFLogxK
U2 - 10.2217/17460816.2.1.105
DO - 10.2217/17460816.2.1.105
M3 - Article
VL - 2
SP - 105
EP - 110
JO - Future Rheumatology
JF - Future Rheumatology
SN - 1758-4272
IS - 1
ER -